Jan 8, 2013 by Brian Orelli, PhDAmgen Licenses Nanopartical Technology to Improve Cancer DrugBIND Biosciences' Medicinal Nanoengineering, Accurins, improves targeting of drugs.
Jan 7, 2013 by Brian Orelli, PhDEli Lilly and Partner Show Positive Diabetes Data in 4 TrialsA new promising class of drugs.
Jan 4, 2013 by Brian Orelli, PhDWill Eli Lilly Make an Acquisition in 2013?Will this drugmaker go shopping this year?
Jan 4, 2013 by Brian Orelli, PhDMerck Still Believes 2 Is Better Than 1A third shot at getting a Lipitor-Zetia drug approved.
Jan 3, 2013 by Brian Orelli, PhDBayer-Teva Animal Deal Clears FTCNot a small task given prior animal-health deals.
Jan 3, 2013 by Brian Orelli, PhDPfizer Licenses Spinal Muscular Atrophy Program From RepligenRepligen will get $5 million upfront and potentially another $65 million if future milestones are met.
Dec 31, 2012 by Brian Orelli, PhDFDA OKs First TB Drug in 40 Years Tackling the Disease in a New WayJohnson & Johnson's Sirturo will only be used as a last resort because of potential side effects.
Dec 31, 2012 by Brian Orelli, PhD2013 Should Be Interesting for Multiple Sclerosis DrugsOral drugs are here to stay.
Dec 31, 2012 by Brian Orelli, PhDAnd the Obesity Plot ThickensThere's more than just Arena's Belviq and VIVUS' Qsymia.
Dec 27, 2012 by Brian Orelli, PhDPharma's High Risk, High Reward Bet Promo The search for the elusive effective Alzheimer's disease drug.
Dec 26, 2012 by Brian Orelli, PhDIs Eli Lilly in Good Hands?Does Eli Lilly's management inspire confidence or doubt?
Dec 26, 2012 by Brian Orelli, PhDMedifast's Acting CFO Resigns After a Month on the JobTwo CFOs resign in as many months.
Dec 26, 2012 by Brian Orelli, PhDBristol-Myers and Pfizer Gain Japanese Approval for EliquisThird approval following the EU and Canada.
Dec 24, 2012 by Brian Orelli, PhDMerry Drugmas! 4 FDA Approvals in 1 DayThat's got to be a sign of a happy new year for drugmakers.
Dec 21, 2012 by Brian Orelli, PhDPfizer Licenses Halozyme's Enhanze TechnologyDeal includes $8 million upfront with the potential for $507 million in additional payments.
Dec 20, 2012 by Brian Orelli, PhDFlush That Outcomes StudyMerck's Cordaptive fails to improve cardiovascular outcomes.
Dec 20, 2012 by Brian Orelli, PhDVertex Updates Incivek Label to Note Fatal Skin ReactionsBoxed warning highlights the severity of the potential side effect.
